2007: ACR Business Meeting and Late-Breaking Abstracts
Search
or
Browse by Day
ACR Business Meeting and Late-Breaking Abstracts
Saturday, November 10, 2007
L13
Mycophenolate Mofetil and Intravenous Cyclophosphamide in the Aspreva Lupus Management Study (ALMS): Efficacy by Racial Group
L14
Golimumab, A New, Human, TNF-alpha Antibody Administered As A Monthly Subcutaneous Injection In Psoriatic Arthritis: 24-week Efficacy And Safety Results Of The Randomized, Placebo-Controlled GO-REVEAL Study
L15
IL-6 Receptor Inhibition with Tocilizumab Reduces Disease Activity in Patients with Rheumatoid Arthritis with Inadequate Response to a Range of DMARDs: The TOWARD Study
L16
Phase II, Randomized, Placebo-Controlled Study of CNTO 1275, a Human Interleukin-12/23 Monoclonal Antibody, in Psoriatic Arthritis
L17
Remission Rates in Subjects With Active Early Rheumatoid Arthritis - 1 Year Results of the COMET Trial:
Co
mbination of
M
ethotrexate and
Et
anercept in Active Early Rhuematoid Arthritis
L18
Pediatric Randomized Placebo-Controlled Trial of Alendronate for Glucocorticoid-Associated Osteoporosis
See more of:
Late-Breaking Abstracts ACR Concurrent Abstract Session
<< Previous Session Level
|
Next Session Level >>